Evidence map›Paper›PMID 38095649›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2024

Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma.

Israa Habeeb Naser, Muhaned Zaid, Eyhab Ali, Hayder Imad Jabar, Anfal Nabeel Mustafa, Mahmood Hasen Shuhata Alubiady, Montather F Ramadan, Khursheed Muzammil, Reem Mohsin Khalaf, Sarah Salah Jalal and 2 more

RetractedAbstract readReviewRetracted Publication
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 3 countries.

Israa Habeeb NaserMedical Laboratories Techniques Department, AL-Mustaqbal University, Hillah, Babil, Iraq.
Muhaned ZaidDepartment of Pharmacy, Al-Manara College for Medical Sciences, Maysan, Amarah, Iraq.
Eyhab AliAl-Zahraa University for Women, Karbala, Iraq.
Hayder Imad JabarDepartment of Pharmaceutics, College of Pharmacy, University of Al-Ameed, Karbala, Iraq.
Anfal Nabeel MustafaDepartment of Pharmacy, Al-Noor University College, Nineveh, Iraq.
Mahmood Hasen Shuhata AlubiadyDepartment of Pharmacy, Al-Hadi University College, Baghdad, Iraq.
Montather F RamadanCollege of Dentistry, Al-Ayen University, Thi-Qar, Iraq.
Khursheed MuzammilDepartment of Public Health, College of Applied Medical Sciences, Khamis Mushait Campus, King Khalid University, Abha, Saudi Arabia.
Reem Mohsin KhalafDepartment of Pharmacy, Mazaya University College, Annasiriyah, Iraq.
Sarah Salah JalalCollege of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq.
Ahmed Hussien AlawadiCollege of Technical Engineering, the Islamic University, Najaf, Iraq.
Ali AlsalamyCollege of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, Iraq. shadisadegh77@gmail.com.
Thi Qar University · IQUniversity of Kerbala · IQAl-Nisour University College · IQAlrafidain University College · IQImam Sadiq University · IRKing Khalid University · SAMazaya University CollegeUniversity of Babylon · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This comprehensive review delineates the latest advancements in stimuli-responsive drug delivery systems engineered for the targeted treatment of breast carcinoma. The manuscript commences by introducing mammary carcinoma and the current therapeutic methodologies, underscoring the urgency for innovative therapeutic strategies. Subsequently, it elucidates the logic behind the employment of stimuli-responsive drug delivery systems, which promise targeted drug administration and the minimization of adverse reactions. The review proffers an in-depth analysis of diverse types of stimuli-responsive systems, including thermoresponsive, pH-responsive, and enzyme-responsive nanocarriers. The paramount importance of material choice, biocompatibility, and drug loading strategies in the design of these systems is accentuated. The review explores characterization methodologies for stimuli-responsive nanocarriers and probes preclinical evaluations of their efficacy, toxicity, pharmacokinetics, and biodistribution in mammary carcinoma models. Clinical applications of stimuli-responsive systems, ongoing clinical trials, the potential of combination therapies, and the utility of multifunctional nanocarriers for the co-delivery of assorted drugs and therapies are also discussed. The manuscript addresses the persistent challenge of drug resistance in mammary carcinoma and the potential of stimuli-responsive systems in surmounting it. Regulatory and safety considerations, including FDA guidelines and biocompatibility assessments, are outlined. The review concludes by spotlighting future trajectories and emergent technologies in stimuli-responsive drug delivery, focusing on pioneering approaches, advancements in nanotechnology, and personalized medicine considerations. This review aims to serve as a valuable compendium for researchers and clinicians interested in the development of efficacious and safe stimuli-responsive drug delivery systems for the treatment of breast carcinoma.

Indexed as

Antineoplastic AgentsBreast NeoplasmsDrug Delivery SystemsAnimalsDrug CarriersFemaleHumansNanoparticlesAntineoplastic AgentsDrug CarriersDrug delivery systemsDrug resistanceMammary carcinomaNanocarriersPrecision therapyStimuli-responsive

Identifiers

PMID38095649
OpenAlexW4389734967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.